Back to SGMOView Full LandscapeView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
9 competitors in Sickle Cell Disease
TRAXSickle cell gene-editing therapy (name not stated)
AGIOTebapivat
AGIOmitapivat
NVOetavopivat
VRTXCasgevy
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Developer
Related Pipeline
CERE-120: Adeno-Associated Virus Delivery of NeurturinPhase 2
Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection SurgeryPhase 2
Alzheimer's Disease
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin)Phase 2
Idiopathic Parkinson's Disease
TX200-TR101Phase 2
Kidney Transplant Rejection
ST-920Phase 2
Fabry Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
